Video
CAR T-Cell Therapies, Antibody-Specific Therapies Are in the Pipeline for Multiple Myeloma
Pharmacists should keep an eye on the pipeline for autologous and allogeneic CAR T-cell therapies as well as antibody-specific treatments.
Several important drug classes are being investigated for use in the treatment of multiple myeloma, according to Jeff Pohler, RPh, senior director of precision medicine at Alliance Rx Walgreens Prime.
In an interview with Pharmacy Times®, Pohler said pharmacists should keep an eye on the pipeline for autologous and allogeneic CAR T-cell therapies as well as antibody-specific treatments. In addition, Pohler discussed how the COVID-19 pandemic impacted treatment for multiple myeloma and how pharmacists can monitor patients with more treatments moving into the home environment.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
